🔎 Trials Near Me

Почетна › Немалоклетни карцином плућа › Орегон

Kliničke studije za Немалоклетни карцином плућа u državi Орегон

62 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Орегон.

Gradovi u državi Орегон

Zvanični tekst studije (na engleskom)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  • Providence Cancer Institute Franz Clinic, Portland
  • Providence St. Vincent Medical Center, Portland
  • Oregon Health and Science University, Portland
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07100080

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  • St. Charles Health System, Inc ( Site 0146), Bend
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Providence Hood River Memorial Hospital, Hood River
  • Providence Newberg Medical Center, Newberg
  • Providence Willamette Falls Medical Center, Oregon City
  • и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Good Samaritan Hospital, Corvallis
  • Three Rivers Community Hospital, Grants Pass
  • Asante Rogue Regional Medical Center, Medford
  • и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  • Oregon Health and Science University ( Site 0052), Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06312137

A Study of DS-3939a in Participants With Solid Tumors

  • Oregon Health & Science University, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07739966

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  • Local Institution - 0404, Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07680790

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217), Corvallis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06623422

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • OHSU Knight Cancer Institute, Beaverton, Beaverton
  • Oncology Associates of Oregon, P.C., Eugene
  • OHSU Knight Cancer Institute, Gresham, Gresham
  • и још 10
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07144280

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Oregon Health and Science University, Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Oncology Associates Of Oregon, Pc, Eugene
  • Northwest Cancer Specialists, P.C., Happy Valley
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07361497

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
  • Kaiser Permanente Interstate Medical Office Central, Portland
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06890598

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Oncology Associates of Oregon, P.C., Eugene
  • Compass Oncology - Rose Quarter, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Kaiser Permanente Northwest, Portland
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • USO - Oncology Associates of Oregon, Eugene
  • Asante Rogue Regional Medical Center, Medford
  • Providence Portland Medical Center, Portland
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  • OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07397338

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  • Providence Cancer Center, Portland
  • Providence Oncology and Hematology Care Clinic Westside, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07586202

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Good Samaritan Hospital, Corvallis
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT03191149

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

  • Providence Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07542704

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Asante Rogue Region al Medical Center, Medford
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06303505

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • Clackamas Radiation Oncology Center, Clackamas
  • Providence Newberg Medical Center, Newberg
  • Providence Willamette Falls Medical Center, Oregon City
  • и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07293247

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117), Corvallis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06170788

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  • Oregon Health And Science University, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06667908

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  • Williamette Valley Cancer Institute and Research Center, Eugene
  • Providence Portland Medical Center, Portland
  • Providence Oncology & Hematology Care Clinic - Westside, West Haven-Sylvan
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07288177

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  • Providence Cancer Institute, Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07195695

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
  • Local Institution - 007-885B, Portland
  • Local Institution - 007-885A, Portland
  • и још 2
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT04613596

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA15-0, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06953089

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  • Providence Cancer Institute, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT05098132

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Medford
  • Research Site, Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738

A Study of MGC026 in Participants With Advanced Solid Tumors

  • Providence Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  • St. Charles Health System, Bend
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06899126

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Oregon Health and Science University, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07154290

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

  • OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07405086

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

  • Oregon Health & Science University, Portland
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 13. 10. 2026. · NCT05317858

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Kaiser Permanente Northwest, Portland
  • Oregon Health and Science University, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Kaiser Permanente Northwest, Portland
Тражи се учесникФаза 2
18 Minutes · Оба пола · Ажурирано 9. 10. 2026. · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Kaiser Permanente Northwest, Portland
  • и још 1
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06616584

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Northwest Cancer Specialists, P.C, Happy Valley
  • Northwest Cancer Specialists, P.C., Portland
  • Northwest Cancer Specialists, P.C, Tigard
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07222566

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  • Oncology Associates of Oregon, P.C., Eugene
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07227298

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Oregon Health & Science University (OHSU), Portland
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.